iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEK)

Category Sector Equity Biotechnology
star-filledstar-filledstar-filledstar-filled
This ETF can be held in an Investment ISA, SIPP and Investment Account
Sell

£5.00

Buy

£5.0075

arrow-up£0.00675 (+0.14%)

Prices updated at 17 Mar 2025, 15:38 GMT
| Prices minimum 15 mins delay
|
Prices in GBP
Investment objective
The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index.
FTSE All-Share
arrow-up0.51%
LSE
Important notice: This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website which details further information in relation to sustainability disclosure requirements for retail clients.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.

Portfolio as of 14/03/2025

Asset allocation

Created with Highcharts 7.2.299.87% Stocks- Bonds0.13% Cash- Other0% Not classified
Show long & short position

Geographical breakdown

Continent or country allocation (%)

Created with Highcharts 7.2.21.311.311.351.353.53.56.016.0187.2687.26Asia - EmergingEurope - ex EuroEurozoneUnited KingdomUnited States

Market classification (%)

Created with Highcharts 7.2.21.311.3198.6998.69EmergingDeveloped

Stock style

Large value

36.99%

% Weight
Value
Core
Growth
Large

37

2

6

Medium

8

6

9

Small

6

11

15

Valuation

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology

14.98

14.98
18.13

3.99

3.99
5.23

3.51

3.51
3.51

13.07

13.07
17.15

Growth rate

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology

16.10%

16.10%
15.23%

0.86%

0.86%
0.36%

-13.67%

-13.67%
-12.03%

Top 10 holdings

1
Gilead Sciences Inc
Sector
-
Country
United States
% of assets
10.08774
2
Amgen Inc
Sector
-
Country
United States
% of assets
9.29391
3
Vertex Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
9.03658
4
Regeneron Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
6.98072
5
AstraZeneca PLC ADR
Sector
-
Country
United Kingdom
% of assets
4.37674
6
Alnylam Pharmaceuticals Inc
Sector
-
Country
United States
% of assets
3.02042
7
Biogen Inc
Sector
-
Country
United States
% of assets
1.9695
8
argenx SE ADR
Sector
-
Country
United States
% of assets
1.89129
9
Sanofi SA ADR
Sector
-
Country
France
% of assets
1.68143
10
Summit Therapeutics Inc Ordinary Shares
Sector
-
Country
United States
% of assets
1.48813
Assets in top 10 holdings %

49.83%

Total no. of equity holdings

264.00

Total no. of bond holdings

-

Stock sectors

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Sector Equity Biotechnology

0.00%

Basic materials

-
-

Con cyclical

-
-

Financial svs

-
-

Real estate

-
-

0.00%

Comm services

-
-

Energy

-
-

Industrials

-
-

Technology

-
-

100.00%

Con defensive

-
-

Healthcare

100.00%
-

Utilities

-
-


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.


Any ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
© Copyright 2025 Morningstar. All rights reserved.